M. Hellstrom

A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer

J. Bergh, P. Malmström, S. Margolin, 2011, Acta oncologica.

Imaging of renal scarring

M. Hellström, E. Stokland, R. Sixt, 1999, Acta paediatrica (Oslo, Norway : 1992). Supplement.

Reliability of ultrasonography in identification of reflux nephropathy in children

E. Stokland, S. Hansson, A. Odén, 1994, BMJ.

RADIOTHERAPY : THE MAINSTAY IN THE TREATMENT OF EARLY GLOTTIC CARCINOMA

T. Kennedy, M. Hellstrom, P. Pellitteri, 1991 .

Combinations of gene therapy, tissue transplantation and pharmacotherapeutic techniques in visual system repair

M. Hellstrom, 2010 .

Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial.

R. Greil, J. Bergh, P. Malmström, 2019, Journal of Clinical Oncology.

Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients

R. Greil, J. Bergh, P. Malmström, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial

H. Johansson, T. Hatschek, H. Lindman, 2024, Breast cancer research and treatment.

Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial

M. Fernö, J. Bergh, N. Loman, 2012, Breast Cancer Research and Treatment.